PUBLIC PREFERENCES FOR ORPHAN DRUG FUNDING- RESULTS OF SUBGROUP ANALYSES
Author(s)
Korchagina D1, Aballea S2, Millier A2, Thokagevistk K2, Toumi M3
1Cr, Paris, France, 2Creativ-Ceutical, Paris, France, 3Aix Marseille University, Marseille, France
OBJECTIVES: A previous study reported preferences of the French general population related to orphan drug funding. The present analysis reports the results for subgroups of participants based on their stated awareness regarding rare diseases. METHODS: The study was designed as a discrete choice experiment and included the following attributes: disease disability and mortality, number of patients, availability of alternative treatments, treatment impact on disease disability and survival, treatment safety, uncertainty around therapeutic effect, and annual treatment cost per patient. Participants were presented with 12 questions containing two drugs profiles described according to the attributes and were asked to choose one treatment (or none). The questionnaire was distributed using a web platform. A conditional logit model was used for statistical analyses and included all attributes and a dummy variable corresponding to a choice of no treatment. An interaction between the number of patients and the cost per patient was tested. Four subgroups were analysed: people who claimed being (vs. not being) aware of rare diseases, people who claimed knowing (vs. not knowing) someone suffering from a rare disease. RESULTS: A total of 958 persons participated in the study. The four subgroups constituted 840 vs. 118, 169 vs. 789 participants, respectively. Overall, the preferences in each subgroup were in line with the results for the full population. The attributes having the greatest impact were treatment impact on the survival and uncertainty around therapeutic effect. Unlike other subgroups, the trend for higher preferences towards more prevalent diseases was not observed in the subgroup of participants who were not aware of rare diseases. The participants who had rare disease patients in their entourage demonstrated higher preferences for drugs with higher per patient costs. CONCLUSIONS: Public preferences related to orphan drug funding seem being homogeneous across the population regardless the stated awareness about rare diseases.
Conference/Value in Health Info
2018-09, ISPOR Asia Pacific 2018, Tokyo, Japan
Value in Health, Vol. 21, S2 (September 2018)
Code
PSY39
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Health Care Research
Disease
Rare and Orphan Diseases